Novartis AG Muscle Drug Sales May Reach $4 Billion, According To MorphoSys AG

Novartis AG (NOVN)’s muscle-building drug bimagrumab may reach as much as $4 billion in peak sales, according to the medicine’s co-developer. The forecast is for the use of the treatment, known as BYM338, in all indications, according to Simon Moroney, chief executive officer of MorphoSys AG (MOR), the company that developed the drug for Novartis. He spoke yesterday at an investor event in Munich. Novartis has said it plans to ask regulators for permission to market the drug to treat sporadic inclusion body myositis, a rare disease characterized by weakening muscles, as early as in 2016.

Help employers find you! Check out all the jobs and post your resume.